PEDEvidence@pedevidence

Cagrilintide

What it is & what research shows

Study example available

Cagrilintide is a long-acting amylin analogue investigated for effects on appetite, body weight and glucose-related outcomes. It is distinct from semaglutide, although the two have also been studied together. Human randomized trials have studied cagrilintide alone and in combination with semaglutide in adults with overweight or obesity, including people with type 2 diabetes. Outcomes and eligibility are specific to each trial. [1.1]

One selected study: A 32-week, double-blind phase 2 trial randomized adults with type 2 diabetes to weekly CagriSema, semaglutide or cagrilintide. The primary outcome was change in HbA1c. The trial included 92 adults with type 2 diabetes and BMI of at least 27 who used metformin, with or without an SGLT2 inhibitor: 31 received CagriSema, 31 semaglutide and 30 cagrilintide. A verified dose and schedule have not yet been added to this study summary. HbA1c fell 2.2 percentage points with CagriSema, 1.8 with semaglutide and 0.9 with cagrilintide. CagriSema was superior to cagrilintide, but not semaglutide, for the primary outcome. Weight fell 15.6%, versus 5.1% and 8.1%; gastrointestinal events were usually mild or moderate. This was a small phase 2 trial with 32 weeks of follow-up; the authors called for larger, longer phase 3 studies. [2.1]

Studied methods, not dosing advice. Selected evidence, not a complete literature review or formal quality appraisal. Read the study summary
Sources & reading scope

By PED Evidence · Content reviewed

Source scope is listed with each reference. Prepared by PED Evidence with AI assistance. Independent clinician review has not been completed. Review standards

Evidence summarized on PED Evidence

6 completed summaries

4 human-study reports

4 randomized-trial candidates

3 safety-topic reports

These counts describe completed summaries on this site, not the size of the full literature. Publications can share participants; design labels are discovery metadata, not appraisals.

Filter, save and compare Cagrilintide studies →
More about Cagrilintide: identity, safety & reference details
PeptideMetabolism
Primary research area
Amylin · metabolism & obesity
Regulatory status
Investigational
Evidence level
Human trials
Primary mechanism
Long-acting amylin analogue; appetite and glucose-related signaling
Reference profile available · Coverage varies by section

Also known as AM833

Start with the research

An outcome-specific synthesis has not been prepared for this compound. This is a coverage gap, not evidence that it has no effect.

Open studies and trial records
Uses & research

Human randomized trials have studied cagrilintide alone and in combination with semaglutide in adults with overweight or obesity, including people with type 2 diabetes. Outcomes and eligibility are specific to each trial. [1]

Known half-life

No source-verified value in this profile yet. A treatment schedule or duration of an effect is not a drug half-life.

Half-life describes how quickly the measured drug concentration falls by half. It does not set a dosing interval.
Evidence & important limits

Cagrilintide remains investigational in the sources used for this profile. Trial results are not a general recommendation, and combination findings should not be assigned automatically to cagrilintide alone. A source-verified half-life is not included here. [1]

Safety & evidence boundaries

Source-specific information, not a personal safety clearance or monitoring plan.

Cagrilintide remains investigational in the sources used for this profile. Trial results are not a general recommendation, and combination findings should not be assigned automatically to cagrilintide alone. A source-verified half-life is not included here.

PubMed cagrilintide clinical-trial search
Explore safety questions by system

These are literature filters, not claims that this compound causes each effect. A keyword match is not a confirmed adverse reaction.

Heart, blood pressure & lipidsLiver injuryKidney functionGlucose effectsReproductive & endocrine effectsMood & sleepAdverse effects & interactions

Interactions, rare harms, long-term effects and reversibility require separate evidence. Do not infer they are absent when the sources here do not address them.

Identity, names & formulations

Canonical compound: Cagrilintide · cagrilintide

Searchable names: AM833

Names share a parent research page. Different esters, salts, routes and brands are not assumed to have the same half-life, indication or exposure.

Combination evidence stays attached to the studied combination. It is not automatically assigned to each ingredient.

Understand the evidence types

Read the model and design first, then the population, outcome and limitations. These categories describe evidence, not a best-compound ranking.

Randomized human trials
Compare assigned interventions. Randomization does not by itself establish low bias or relevance to every population.
Controlled human studies
Use a comparison group; allocation and confounding still matter.
Prospective human research
Follows participants forward. It may be observational or interventional, so this is not a separate quality grade.
Observational human research
Describes associations. Confounding can explain differences.
Case reports and series
Useful for unusual events and safety signals, not reliable rates or effect sizes.
Animal research
Can test biology and function in a living model. Human exposure, benefit and safety remain separate questions.
Cell and tissue research
Tests responses in a preparation, including human-derived cells. It is not a human participant trial.
Mechanistic and computational evidence
Helps explain or predict a pathway; predictions need experimental and clinical testing.
Anecdotal reports
Self-reported experiences can generate questions. Product identity, selection bias and other interventions may be uncontrolled.

Systematic reviews synthesize studies and depend on their quality. Preprint status and abstract versus full-paper reading are separate labels. Citation popularity measures attention, not reliability. A study summary is not a formal quality appraisal.

Related compounds

Sources for this profile

  1. 1. PubMed cagrilintide clinical-trial search Scientific database search · human obesity and metabolic trials

Reference facts checked 2026-09-16. Source scope is listed above; this is not a formal quality appraisal. See each label for full prescribing information.

Browse all studies

Study model describes the source. Confidence depends on methods, replication, population and outcome.

Loading compound research…

Cagrilintide study summaries

Human-first reading order. Intervention candidates are distinguished from background mentions in the library.